Form D · Biotechnology
ST Phi Therapeutics, Inc.
Seattle, WA · CIK 0001727316
Offering snapshot reported Jan 9, 2018 · SEC filing
- Reported sold
- $500K Offering amount: $500K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 1, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 9, 2018 | Initial | $500,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-302739
Source: Form D, filed Jan 9, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Xiaobin Guo | Director, Executive |
| Lingfeng Liu | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Startup Hall, Box 354625 1100 Ne Campus Parkway, Suite 200
Seattle, WA, 98195
Seattle, WA, 98195